FY2025 EPS Estimates for Chemours Lowered by Zacks Research

The Chemours Company (NYSE:CC) – Stock analysts at Zacks Research lowered their FY2025 earnings estimates for shares of Chemours in a report issued on Wednesday, November 19th. Zacks Research analyst Team now anticipates that the specialty chemicals company will post earnings of $0.92 per share for the year, down from their previous forecast of $1.30. Zacks Research currently has a “Strong Sell” rating on the stock. The consensus estimate for Chemours’ current full-year earnings is $2.03 per share. Zacks Research also issued estimates for Chemours’ Q4 2025 earnings at $0.01 EPS, Q1 2026 earnings at $0.20 EPS, Q3 2026 earnings at $0.57 EPS, FY2026 earnings at $1.74 EPS, Q2 2027 earnings at $0.66 EPS, Q3 2027 earnings at $0.70 EPS and FY2027 earnings at $2.30 EPS.

A number of other analysts also recently weighed in on the stock. Royal Bank Of Canada reduced their target price on shares of Chemours from $19.00 to $17.00 and set an “outperform” rating on the stock in a research report on Monday, November 10th. Truist Financial dropped their price objective on shares of Chemours from $21.00 to $18.00 and set a “buy” rating on the stock in a report on Monday, November 10th. Weiss Ratings restated a “sell (d)” rating on shares of Chemours in a research note on Wednesday, October 8th. Mizuho lowered their target price on shares of Chemours from $19.00 to $18.00 and set an “outperform” rating on the stock in a report on Thursday, October 16th. Finally, UBS Group decreased their target price on shares of Chemours from $21.00 to $18.00 and set a “buy” rating on the stock in a research report on Tuesday, November 11th. Five analysts have rated the stock with a Buy rating, three have issued a Hold rating and two have issued a Sell rating to the company’s stock. Based on data from MarketBeat, the stock presently has a consensus rating of “Hold” and a consensus target price of $17.50.

Chemours Stock Performance

Chemours stock opened at $11.06 on Friday. The company has a debt-to-equity ratio of 13.66, a quick ratio of 0.88 and a current ratio of 1.71. The firm’s fifty day moving average price is $14.03 and its 200-day moving average price is $13.18. Chemours has a fifty-two week low of $9.13 and a fifty-two week high of $22.38. The stock has a market cap of $1.66 billion, a P/E ratio of -4.98 and a beta of 1.64.

Chemours (NYSE:CC) last posted its quarterly earnings data on Thursday, November 6th. The specialty chemicals company reported $0.20 earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $0.24 by ($0.04). Chemours had a positive return on equity of 35.27% and a negative net margin of 5.70%.The company had revenue of $1.50 billion for the quarter, compared to analysts’ expectations of $1.50 billion. During the same quarter last year, the business posted $0.40 EPS. The business’s quarterly revenue was down .9% on a year-over-year basis. Chemours has set its Q4 2025 guidance at EPS. FY 2025 guidance at EPS.

Chemours Announces Dividend

The firm also recently declared a quarterly dividend, which will be paid on Monday, December 15th. Shareholders of record on Friday, November 14th will be issued a $0.0875 dividend. This represents a $0.35 annualized dividend and a yield of 3.2%. The ex-dividend date of this dividend is Friday, November 14th. Chemours’s dividend payout ratio (DPR) is currently -15.77%.

Institutional Trading of Chemours

Several large investors have recently added to or reduced their stakes in CC. CIBC Bancorp USA Inc. purchased a new position in shares of Chemours during the third quarter worth $254,000. Caitong International Asset Management Co. Ltd purchased a new position in Chemours during the third quarter valued at $43,000. Advisory Services Network LLC acquired a new position in Chemours in the 3rd quarter valued at $54,000. CANADA LIFE ASSURANCE Co boosted its position in Chemours by 6.5% during the third quarter. CANADA LIFE ASSURANCE Co now owns 131,336 shares of the specialty chemicals company’s stock worth $2,048,000 after acquiring an additional 8,028 shares during the last quarter. Finally, Steadfast Capital Management LP acquired a new stake in shares of Chemours in the third quarter valued at approximately $7,730,000. Hedge funds and other institutional investors own 76.26% of the company’s stock.

Chemours Company Profile

The Chemours Company provides performance chemicals in North America, the Asia Pacific, Europe, the Middle East, Africa, and Latin America. It operates through three segments: Titanium Technologies, Thermal & Specialized Solutions, and Advanced Performance Materials. The Titanium Technologies segment provides TiO2 pigment under the Ti-Pure brand for delivering whiteness, brightness, opacity, durability, efficiency, and protection in various of applications, such as architectural and industrial coatings, flexible and rigid plastic packaging, polyvinylchloride, laminate papers used for furniture and building materials, coated paper, and coated paperboard used for packaging.